Preclinical, Publications Discovery of a Liver-Targeted PD-L1 Small Molecule Inhibitor for the Treatment of Chronic Hepatitis B and Liver Cancer
ALG-055009, Publications Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Multiple Ascending Oral Doses of ALG-055009, a Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of Non-Alcoholic Steatohepatitis (NASH), in Healthy Volunteers and Subjects with Hyperlipidaemia
ALG-000184, Publications Preclinical Antiviral, Pharmacological and Toxicological Characteristics of ALG-000184, a Prodrug of the Novel HBV Capsid Assembly Modulator ALG‑001075
ALG-000184, Publications The Capsid Assembly Modulator ALG-000184 Dosed for 28 Days Was Well Tolerated and Rapidly Reduced Viral Markers in Subjects with Chronic Hepatitis B, Including HBsAg in a Subset of HBeAg Positive Subjects with Elevated Baseline ALT
ALG-000184, Publications ALG-000184, a Capsid Assembly Modulator, Demonstrates Superior Antiviral Activity in Combination with Entecavir Compared to Entecavir in HBeAg Positive Subjects with Chronic Hepatitis B infection
Publication, Publications The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir
ALG-097558, Publications Preclinical Evaluation of ALG-097558:A Novel, Orally Bioavailable Pan-Coronavirus 3CLpro Inhibitor for the Treatment of COVID-19
ALG-000184, Publications The Prodrug of a Novel Capsid Assembly Modulator (CAM), ALG-000184, Demonstrates a Favorable Nonclinical Toxicokinetic and Toxicology Profile for the Treatment of Chronic Hepatitis B (CHB)
Preclinical, Publications Discovery of Liver-targeted Oral PD-L1 Small Molecule Inhibitors for the Treatment of Chronic Hepatitis B and Liver Cancers